Waystar announced on July 23, 2025, a definitive agreement to acquire 100% of Iodine Software for a total enterprise value of $1.25 billion. This acquisition is expected to accelerate Waystar's ability to transform healthcare payments through its cloud-based software platform, empowering over one million providers with advanced AI capabilities.
The transaction will be funded with a 50/50 mix of cash and stock consideration and is anticipated to close by year-end 2025, subject to regulatory approvals. Waystar expects the acquisition to be immediately accretive to gross margin and adjusted EBITDA margin, and accretive to revenue growth and non-GAAP net income per diluted share in 2027.
Iodine Software is recognized for its AI-powered clinical intelligence software, leveraging proprietary AI models trained on one of the industry's largest clinical datasets. This acquisition extends Waystar's AI leadership into clinical intelligence, aiming to decrease the estimated $440 billion in annual administrative costs and expand Waystar's total addressable market by over 15%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.